Advanced cell therapy, delivered closer to home
BioOra develops and manufactures next-generation CAR-T therapies from New Zealand. Improving access, reducing delays, and enabling safe, more scalable delivery of treatments.
EARLY CLINICAL OBSERVATIONS
from BioOra’s lead programme
Encouraging complete response rates and favourable safety profile in participants treated in the Phase 1 clinical trial.
Read the clinical data.
Results are preliminary and subject to change as trials progress.
This therapy is not yet approved.
Why access to CAR-T therapy matters
Limited access today
Advanced cell therapies are still difficult to access outside major global centres, with cost, capacity, and location creating barriers for many patients.
Time matters
For eligible patients, delays in treatment can significantly impact outcomes, while complex delivery pathways can further limit access.
Closer delivery changes this
Delivering CAR-T therapies locally improves access, shortens timelines, and supports more efficient, scalable delivery of treatment.
DESIGNED FOR BETTER OUTCOMES
Advancing CAR-T therapies with a focus on patients
BioOra’s approach prioritises what matters most:
Improved tolerability
Designed to reduce severe side effects associated with traditional CAR-T therapiesFaster access to treatment
Local delivery reduces delays between diagnosis and therapyConsistent, scalable delivery
Enabling broader access through a more efficient and scalable model of treatment deliveryAutomated, scalable manufacturing
Using the Cocoon® platform to enable consistent production and scalable delivery from New Zealand across the region
HOW CAR-T THERAPY WORKS
A patient’s own immune system, reprogrammed to deliver targeted treatment
Unlike traditional treatments that require ongoing administration, CAR-T is a one-off, living therapy that continues working inside the body.
Cells are collected
T-cells are taken from the patient’s blood
Cells are engineered
These cells are modified to recognise and target cancer cells
Cells are returned
The engineered cells are infused back into the patient
Cancer is targeted
The cells identify and destroy cancer cells within the body
BUILDING FROM NEW ZEALAND, SCALING GLOBALLY
Expanding access through a next-generation approach
BioOra is developing next-generation therapies and building a scalable model for their delivery — designed to address key limitations of existing treatments across safety, access, and scalability.
With global rights secured to our lead programme asset, BioOra is positioned to expand across the United States, Europe, and Asia Pacific.
This positions BioOra to:
Extend access to advanced therapies across underserved regions
Partner with global institutions to broaden clinical applications
Deliver CAR-T therapies through a more scalable and accessible model
FOR CLINICIANS, PARTNERS, AND INVESTORS
Join us in advancing the future of cell therapy in New Zealand and beyond
For clinicians
Access the clinical data
Learn more about eligibility criteria, and referral pathways
For partners
Collaborate to bring new CAR-T therapies to patients faster.
partners@bioora.com
For investors
Support a scalable model for delivering advanced therapies globally.
Contact Form
